Home >> Research Area >>Others>>Others>> R-(-)-Deprenyl hydrochloride

R-(-)-Deprenyl hydrochloride

MAO-B inhibitor CAS# 14611-52-0

R-(-)-Deprenyl hydrochloride

Catalog No. BCC5196----Order now to get a substantial discount!

Product Name & Size Price Stock
R-(-)-Deprenyl hydrochloride: 5mg Please Inquire In Stock
R-(-)-Deprenyl hydrochloride: 10mg Please Inquire In Stock
R-(-)-Deprenyl hydrochloride: 20mg Please Inquire Please Inquire
R-(-)-Deprenyl hydrochloride: 50mg Please Inquire Please Inquire
R-(-)-Deprenyl hydrochloride: 100mg Please Inquire Please Inquire
R-(-)-Deprenyl hydrochloride: 200mg Please Inquire Please Inquire
R-(-)-Deprenyl hydrochloride: 500mg Please Inquire Please Inquire
R-(-)-Deprenyl hydrochloride: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of R-(-)-Deprenyl hydrochloride

Number of papers citing our products

Chemical structure

R-(-)-Deprenyl hydrochloride

3D structure

Chemical Properties of R-(-)-Deprenyl hydrochloride

Cas No. 14611-52-0 SDF Download SDF
PubChem ID 26758 Appearance Powder
Formula C13H18ClN M.Wt 223.74
Type of Compound N/A Storage Desiccate at -20°C
Synonyms Selegiline
Solubility Soluble to 100 mM in water
Chemical Name (2R)-N-methyl-1-phenyl-N-prop-2-ynylpropan-2-amine;hydrochloride
SMILES CC(CC1=CC=CC=C1)N(C)CC#C.Cl
Standard InChIKey IYETZZCWLLUHIJ-UTONKHPSSA-N
Standard InChI InChI=1S/C13H17N.ClH/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13;/h1,5-9,12H,10-11H2,2-3H3;1H/t12-;/m1./s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of R-(-)-Deprenyl hydrochloride

DescriptionSelective inhibitor of monoamine oxidase B (MAO-B).

R-(-)-Deprenyl hydrochloride Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

R-(-)-Deprenyl hydrochloride Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of R-(-)-Deprenyl hydrochloride

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 4.4695 mL 22.3474 mL 44.6947 mL 89.3895 mL 111.7368 mL
5 mM 0.8939 mL 4.4695 mL 8.9389 mL 17.8779 mL 22.3474 mL
10 mM 0.4469 mL 2.2347 mL 4.4695 mL 8.9389 mL 11.1737 mL
50 mM 0.0894 mL 0.4469 mL 0.8939 mL 1.7878 mL 2.2347 mL
100 mM 0.0447 mL 0.2235 mL 0.4469 mL 0.8939 mL 1.1174 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on R-(-)-Deprenyl hydrochloride

R-(-)-Deprenyl Hydrochloride is a selective inhibitor of monoamine oxidase B (MAO-B).

Featured Products
New Products
 

References on R-(-)-Deprenyl hydrochloride

In vitro interactions of amantadine hydrochloride, R-(-)-deprenyl hydrochloride and valproic acid sodium salt with antifungal agents against filamentous fungal species causing central nervous system infection.[Pubmed:23134606]

Acta Biol Hung. 2012 Dec;63(4):490-500.

The mortality rates of fungal infections that affect the central nervous system are high in consequence of the absence of effective antifungal drugs with good penetration across the blood-brain barrier and the blood-cerebrospinal fluid barrier. In the present work in vitro antifungal activities of three good penetrating non-antifungal drugs (amantadine hydrochloride, R-(-)-Deprenyl hydrochloride, valproic acid sodium salt) and their combinations with three antifungal agents (amphotericin B, itraconazole, terbinafine) were tested with broth microdilution method against eight fungal isolates belonging to Zygomycetes (Lichtheimia corymbifera, Rhizomucor miehei, Rhizopus microsporus var. rhizopodiformis, Saksenaeavasiformis) and Aspergillus genus (A. flavus, A. fumigatus, A. nidulans, A. terreus). These are known to be possible agents of central nervous fungal infections (CNFI). When used alone, the investigated nonantifungal drugs exerted slight antifungal effects. In their combinations with antifungal agents they acted antagonistically, additively and synergistically against zygomyceteous isolates. Primarily antagonistic interactions were revealed between the investigated drugs in case of Aspergilli, but additive and synergistic interactions were also observed. The additive and synergistic combinations allowed the usage of reduced concentrations of antifungal agents to inhibit the fungal growth in our study. These combinations would be a basis of an effective, less toxic therapy for treatment of CNFI.

Effect of selegiline on dopamine concentration in the striatum of a primate.[Pubmed:9974121]

Brain Res. 1999 Jan 2;815(1):44-50.

Monoamine oxidase (MAO) has two subtypes, A and B, that have different distributions between the rodent and the human. In the striatum, dopamine (DA) of the rat seems to be metabolized by MAO A, and DA of the human is largely deaminated by MAO B. MAO in the striatum of common marmosets is also type B. Using in vivo microdialysis, we investigated the pharmacological activity of selegiline, a selective irreversible inhibitor of MAO B, in the striatum of marmosets. Intraperitoneal co-administration of selegiline (1 mg kg-1, i.p.) with levodopa/carbidopa (10/2.5 mg kg-1, i.p.) did not significantly increase extracellular concentration of DA in the striatum of common marmosets compared with control animals receiving levodopa/carbidopa alone. Daily pretreatment with 0.1 mg kg-1 (i.p.) selegiline for two weeks, however, dramatically increased extracellular concentration of DA to about seven times that of control animals treated with levodopa/carbidopa alone in marmosets. Such an increase in extracellular concentrations of DA could not be observed in a similar study with Wistar rats. This study showed that chronic administration of a small dose of selegiline caused a marked increase in extracellular DA concentration in the striatum of primates, but not in the rodents.

Deprenyl decreases an endogenous parkinsonism-inducing compound, 1-benzyl-1,2,3,4-tetrahydroisoquinoline in mice: in vivo and in vitro studies.[Pubmed:9518683]

Brain Res. 1998 Mar 23;787(2):341-3.

We examined the effect of deprenyl, a promising drug for the therapy of Parkinson's disease on the formation of a parkinsonism-inducing compound, 1-benzyl-1,2,3,4-tetrahydroisoquinoline (1BnTIQ). The 1BnTIQ content was significantly decreased in the brain of deprenyl-treated mouse in vivo, and deprenyl also inhibited 1BnTIQ formation from phenethylamine by a mouse brain homogenate supernatant in vitro. In vivo, the content of a parkinsonism-preventing compound, 1-methyl-1,2,3, 4-tetrahydroisoquinoline (1MeTIQ) was slightly increased in mice injected with deprenyl. The marked decrease of the ratio of 1BnTIQ to 1MeTIQ might play a role in the clinical effect of deprenyl.

Modification of levodopa responses by deprenyl (selegiline): an electrophysiological and behavioral study in the rat relevant to Parkinson's disease.[Pubmed:9585355]

Ann Neurol. 1998 May;43(5):613-7.

From using in vitro intracellular recordings from mesencephalic neurons and monoamine-depleted rats, we report that the functions of levodopa in the brain are greatly enhanced and prolonged by high doses of the monoamine oxidase (MAO) inhibitor deprenyl. Dopaminergic neurons were hyperpolarized and inhibited by levodopa application. These effects of levodopa were largely potentiated by pretreatment with nonselective doses of deprenyl. Furthermore, when locomotor activity induced by levodopa was examined on a rodent model of Parkinson's disease, pretreatment of the animals with nonselective doses of deprenyl caused an enhancement of the antiparkinsonian action of levodopa. The great increase in levodopa responses by deprenyl suggests a likely therapeutic use of this dopamine precursor with a higher dosage of the MAO inhibitor, to reduce effectively the daily levodopa requirements in Parkinson's disease patients.

The molecular pharmacology of L-deprenyl.[Pubmed:1639115]

Eur J Pharmacol. 1992 Jun 5;226(2):97-108.

L-Deprenyl, the selective inhibitor of monoamine oxidase type B (MAO-B), has gained wide acceptance as a useful form of adjunct therapeutic drug in the treatment of Parkinson's disease. This review summarizes the molecular pharmacology of L-deprenyl, and the advances in our understanding of its possible mode of action in Parkinson's disease. L-Deprenyl belongs to the class of enzyme-activated irreversible inhibitors also described as 'suicide' inhibitors, because the compound acts as a substrate for the target enzyme, whose action on the compound results in irreversible inhibition. L-Deprenyl first of all forms a noncovalent complex with MAO as an initial, reversible step. The subsequent interaction of L-deprenyl with MAO leads to a reduction of the enzyme-bound flavin-adenine dinucleotide (FAD), and concomitant oxidation of the inhibitor. This oxidized inhibitor then reacts with FAD at the N-5-position in a covalent manner. The observed in vitro selectivity of L-deprenyl for MAO-B may be accounted for by differences in the affinities of the two MAO subtypes for reversible interaction with L-deprenyl, differences in the rates of reaction within the noncovalent complexes to form the irreversibly inhibited adduct, or a combination of both these factors. However, if selective inhibition is to be maintained in vivo, correct dosage schedules are critically important, since all selective MAO inhibitors described up to now lack selectivity at high doses. In experimental animals L-deprenyl is protective against the damaging effects of several neurotoxins, including the dopaminergic agents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 6-hydroxydopamine (6-OHDA) and the noradrenergic neurotoxin N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4). Beside MAO-B inhibition, which above all explains the prevention of neurotoxic action of MPTP by preventing its metabolism, L-deprenyl appears to exhibit other mechanisms of action which are independent of its action on MAO-B.

Description

R-(-)-Deprenyl Hydrochloride is a selective inhibitor of monoamine oxidase B (MAO-B).

Keywords:

R-(-)-Deprenyl hydrochloride,14611-52-0,Selegiline,Natural Products,Others, buy R-(-)-Deprenyl hydrochloride , R-(-)-Deprenyl hydrochloride supplier , purchase R-(-)-Deprenyl hydrochloride , R-(-)-Deprenyl hydrochloride cost , R-(-)-Deprenyl hydrochloride manufacturer , order R-(-)-Deprenyl hydrochloride , high purity R-(-)-Deprenyl hydrochloride

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: